“…Epigenomic reprogramming has a clearcut role in cancer, be it via transcription factors or chromatin regulators (Dawson and Kouzarides, 2012, Suva et al, 2013). Although access to tissue to define epigenomic signatures is a limiting factor outside of the cancer space, it is apparent that many other diseases are affected by epigenomic dynamics, such as complications of diabetes, rheumatoid arthritis or hypertension (Pirola et al, 2010, Liu et al, 2013, Fratkin et al, 2012). Furthermore, epigenomic changes affect susceptibility to diseases, as has been shown with open chromatin related to the TCF7L2 gene (Groop, 2010) and parental origin of sequence variants for Type 2 diabetes mellitus, breast and prostate cancer (Kong et al, 2009).…”